Floxuridine

Generic Name: Floxuridine

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₉H_₁₁FN_₂O_₅

CAS Number: 50-91-9

Unique Ingredient Identifier: 039LU44I5M

Background: An antineoplastic antimetabolite that is metabolized to fluorouracil when administered by rapid injection. Floxuridine is available as a sterile, nonpyrogenic, lyophilized powder for reconstitution. When administered by slow, continuous, intra-arterial infusion, it is converted to floxuridine monophosphate. It has been used to treat hepatic metastases of gastrointestinal adenocarcinomas and for palliation in malignant neoplasms of the liver and gastrointestinal tract.

Indication: For palliative management of gastrointestinal adenocarcinoma metastatic to the liver, when given by continuous regional intra-arterial infusion in carefully selected patients who are considered incurable by surgery or other means. Also for the palliative management of liver cancer (usually administered by hepatic intra-arterial infusion).

Associated Conditions: Stage 4 gastrointestinal adenocarcinoma

Associated Therapies: Palliative Treatment

Clinical Trials

Veliparib and Floxuridine in Treating Patients With Metastatic Epithelial Ovarian, Primary Peritoneal Cavity, or Fallopian Tube Cancer

Phase 1

Completed

Conditions: Stage IV Ovarian Cancer AJCC v6 and v7
Stage IV Primary Peritoneal Cancer AJCC v7
Stage IV Fallopian Tube Cancer AJCC v6 and v7

Interventions: Drug: Floxuridine
Other: Laboratory Biomarker Analysis
Other: Pharmacological Study
Drug: Veliparib

First Posted Date: 2012-12-13

Last Posted Date: 2020-07-02

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 29

Registration Number: NCT01749397

Locations: 🇺🇸
Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States
🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States
🇺🇸
Siteman Cancer Center at Washington University, Saint Louis, Missouri, United States

and more 2 locations

Hepatic Arterial Infusion in Treating Patients With Locally Advanced, Non-Metastatic Cholangiocarcinoma

Phase 1

Terminated

Conditions: Cholangiocarcinoma
Liver Neoplasms

Interventions: Drug: Floxuridine
Drug: Dexamethasone
Drug: Gemcitabine
Drug: Oxaliplatin

First Posted Date: 2012-02-02

Last Posted Date: 2022-08-10

Lead Sponsor: Washington University School of Medicine

Target Recruit Count: 27

Registration Number: NCT01525069

Locations: 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States

Irinotecan/Cisplatin, Potentially Curative Surgery With or Without Floxuridine, Followed by Capecitabine for Stomach and Gastro-esophageal Junction (GEJ) Cancers

Phase 2

Terminated

Conditions: Gastric Cancer
Esophageal Cancer
Gastric Adenocarcinoma

Interventions: Drug: Irinotecan
Drug: Cisplatin
Procedure: Surgery
Drug: Floxuridine
Drug: Capecitabine

First Posted Date: 2009-02-20

Last Posted Date: 2018-01-08

Lead Sponsor: NYU Langone Health

Target Recruit Count: 8

Registration Number: NCT00848783

Locations: 🇺🇸
Bellevue Hospital, New York, New York, United States
🇺🇸
NYU Cancer Center, New York, New York, United States
🇺🇸
Norris Cancer Center, Los Angeles, California, United States

Hepatic Arterial Infusion of Floxuridine, Gemcitabine Hydrochloride, and Radiolabeled Monoclonal Antibody Therapy in Treating Liver Metastases in Patients With Metastatic Colorectal Cancer Previously Treated With Surgery

Phase 1

Completed

Conditions: Recurrent Rectal Cancer
Stage IV Colon Cancer
Stage IV Rectal Cancer
Recurrent Colon Cancer
Liver Metastases

Interventions: Drug: gemcitabine hydrochloride
Drug: floxuridine
Genetic: proteomic profiling
Other: matrix-assisted laser desorption/ionization time of flight mass spectrometry
Other: liquid chromatography
Radiation: yttrium Y 90 anti-CEA monoclonal antibody cT84.66
Other: laboratory biomarker analysis
Other: mass spectrometry
Other: pharmacological study

First Posted Date: 2008-03-28

Last Posted Date: 2019-03-28

Lead Sponsor: City of Hope Medical Center

Target Recruit Count: 16

Registration Number: NCT00645710

Locations: 🇺🇸
City of Hope, Duarte, California, United States

A Phase II Study of Continuous Hepatic Arterial Infusion With Floxuridine (FUDR) and Dexamethasone (DEX) in Patients With Unresectable Primary Hepatic Malignancy

Phase 2

Completed

Conditions: Hepatic Cancer

Interventions: Drug: FLOXURIDINE

First Posted Date: 2008-01-07

Last Posted Date: 2023-04-04

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 34

Registration Number: NCT00587067

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Hepatic Arterial Infusion With Floxuridine and Dexamethasone Combined With Combination Chemotherapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver

Phase 2

Active, not recruiting

Conditions: Colorectal Cancer
Metastatic Cancer

Interventions: Drug: dexamethasone
Drug: floxuridine
Drug: irinotecan hydrochloride
Drug: fluorouracil
Drug: oxaliplatin
Drug: leucovorin calcium

First Posted Date: 2007-06-27

Last Posted Date: 2024-05-13

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 64

Registration Number: NCT00492999

Locations: 🇺🇸
Memorial Sloan Kettering at Mercy Medical Center, Rockville Centre, New York, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸
Memorial Sloan Kettering Cancer Center@Phelps Memorial Hospital, Sleepy Hollow, New York, United States

and more 1 locations

Combination Chemotherapy in Treating Patients With Previously Untreated Stage II or Stage III Esophageal Cancer That Can Be Removed By Surgery

Phase 2

Completed

Conditions: Esophageal Cancer

Interventions: Drug: Docetaxel
Drug: Floxuridine
Drug: Leucovorin
Drug: Oxaliplatin
Genetic: Microarray analysis
Genetic: reverse transcriptase-polymerase chain reaction
Procedure: Conventional surgery